9-Me-BC is a research compound. It is not approved by the FDA or any regulatory body for human use. This article is for educational and informational purposes only. Nothing here constitutes medical advice. Consult a qualified physician before considering any peptide use.
Reversed dopamine depletion in MPTP neurotoxin models, restoring dopaminergic neurons to normal levels. Improved spatial learning and elevated hippocampal dopamine in 10-day mouse studies. No human clinical trials — preclinical evidence only. 9-Me-BC is not fda-approved. research compound only. unregulated.
What Does the Research Say About 9-Me-BC?
Reversed dopamine depletion in MPTP neurotoxin models, restoring dopaminergic neurons to normal levels. Improved spatial learning and elevated hippocampal dopamine in 10-day mouse studies. No human clinical trials — preclinical evidence only.
9-Me-BC (9-Methyl-β-carboline) is a Monoamine oxidase inhibitor, neuroprotective agent. Research interest has focused on its potential effects on dopamine elevation, neuroprotection, improved spatial learning, enhanced dendritic complexity, cognitive enhancement, potential anti-Parkinsonian activity.
What Is the Evidence for 9-Me-BC's Mechanism?
Inhibits MAO-A (IC50: 1 μM) and MAO-B (IC50: 15.5 μM), preventing dopamine degradation and extending its activity. Simultaneously stimulates neurotrophic factor gene expression including BDNF, GDNF, and ARTN through the PI3K/Akt signaling pathway, promoting both dopaminergic neuron survival and new dendritic growth.
These pathways have been identified through in vitro studies, animal models, and where available, human trials.
Are There Human Clinical Trials for 9-Me-BC?
Reversed dopamine depletion in MPTP neurotoxin models, restoring dopaminergic neurons to normal levels. Improved spatial learning and elevated hippocampal dopamine in 10-day mouse studies. No human clinical trials — preclinical evidence only.
The gap between preclinical promise and clinical validation remains the biggest challenge in peptide research. However, 9-Me-BC has shown encouraging results.
What Does the Safety Research Show?
Dose-dependent toxicity at high concentrations in cell cultures. No human safety data available. As an MAO inhibitor, carries risk of tyramine interactions (avoid aged cheese, cured meats, fermented foods). Photosensitivity reported — avoid UV exposure during use.
9-Me-BC is not fda-approved. research compound only. unregulated.
What Makes 9-Me-BC Unique in Research?
Dual mechanism of MAO inhibition plus neurotrophic factor stimulation makes it unique for dopaminergic restoration — one of the few compounds that both preserves existing dopamine AND grows new dopaminergic neurons.
This differentiator is important because it means 9-Me-BC fills a role that other compounds in its class may not fully replicate.
Bottom Line on 9-Me-BC Research
The evidence base for 9-Me-BC is growing. Key research areas include dopamine elevation, neuroprotection, improved spatial learning, enhanced dendritic complexity, cognitive enhancement, potential anti-Parkinsonian activity.
Stay current with PubMed searches for 9-Me-BC for the latest publications.
Complete Guide
9-Me-BC : Benefits, Dosage, Side Effects & Research
Related Reading
- 9-Me-BC Dosage Guide
- 9-Me-BC Benefits
- 9-Me-BC Side Effects
- 9-Me-BC Stacking Guide
- 9-Me-BC Cycle Guide
- Dihexa Complete Guide
Calculate Your 9-Me-BC Dose
Use our free peptide dosing calculator to get exact reconstitution math and syringe units for 9-Me-BC.
Open Calculator →Research-Grade Sourcing
If you're going to research 9-Me-BC, source matters. These are the suppliers WolveStack has vetted for purity and third-party testing.
Frequently Asked Questions
What is 9-Me-BC?
9-Me-BC (9-Methyl-β-carboline) is a Monoamine oxidase inhibitor, neuroprotective agent. Synthetic indole alkaloid derivative targeting dopaminergic neuroprotection. It is researched for dopamine elevation, neuroprotection, improved spatial learning, enhanced dendritic complexity, cognitive enhancement, potential anti-Parkinsonian activity.
What is the recommended 9-Me-BC dosage?
Common dosages: 15-30 mg daily administered once daily via oral or subcutaneous. Cycle length: 7-10 days (short cycles recommended due to MAO inhibition). Half-life: not established. Use our peptide calculator for exact reconstitution math.
What are the side effects of 9-Me-BC?
Dose-dependent toxicity at high concentrations in cell cultures. No human safety data available. As an MAO inhibitor, carries risk of tyramine interactions (avoid aged cheese, cured meats, fermented foods). Photosensitivity reported — avoid UV exposure during use.
Is 9-Me-BC safe?
9-Me-BC has shown a preliminary safety profile in research. Not FDA-approved. Research compound only. Unregulated. All research should follow appropriate safety protocols.